News & Updates
Filter by Specialty:
Does multiple biosimilar switching induce flare in IBD patients?
17 Feb 2024
byStephen Padilla
Multiple biosimilar infliximab (IFX) switching among patients with inflammatory bowel disease (IBD) does not seem to give rise to disease flares at 12 months compared to those who continued using IFX originator or those on single IFX biosimilar switch, a study has shown.
Does multiple biosimilar switching induce flare in IBD patients?
17 Feb 2024IBD patients see improvements after surgical intervention
15 Feb 2024
byJairia Dela Cruz
A surgical intervention performed for inflammatory bowel disease (IBD) appears to confer favourable effects on patient-reported outcomes such as pain and overall health, according to a prospective, longitudinal cohort study.
IBD patients see improvements after surgical intervention
15 Feb 2024Immunotherapy, TACE-based regimen may reshape HCC treatment landscape
13 Feb 2024
byAudrey Abella
In the EMERALD-1 trial, durvalumab plus bevacizumab (D+B) combined with transarterial chemoembolization (TACE) improved progression-free survival (PFS) in individuals with unresectable hepatocellular carcinoma (HCC) eligible for embolization.